Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-γ and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial

Journal of Clinical Oncology

Volumn 14, Issue 10, 1996, Pages 2653-2665

  Eggermont, A M ^a   Schraffordt Koops, H ^a   Lienard D ^a   Kroon, B B ^a   van Geel, A N ^a   Hoekstra, H J ^a   Lejeune, F J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SURGERY; CLINICAL TRIAL; FEMALE; HUMAN; LIMB PERFUSION; LIMB SALVAGE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; TREATMENT OUTCOME;

EID: 0029738520     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.10.2653     Document Type: Article

References (56)

1. Boring CC, Squires TS, Tong T, et al: Cancer statistics, 1994. Ca Cancer J Clin 44:7-26, 1994
2. Gaynor JJ, Tan CC, Casper ES, et al: Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: A study of 423 adults. J Clin Oncol 10:1317-1327, 1992
3. Suit HD, Tepper JE: Impact of improved local control on survival in patients with soft tissue sarcoma. Int J Radiat Oncol Biol Phys 12:699-700, 1986
4. Brennan MF, Shiu MH, Collin C, et al: Extremity soft tissue sarcomas. Cancer Treat Symp 3:71-81, 1985
5. Potter DA, Kinsella D, Gladstein E et al: High grade soft tissue sarcomas of the extremities. Cancer 59:190-205, 1986
6. Stotter AT, A'Hearn RP, Fisher C, et al: The influence of local recurrence of extremity soft tissue sarcoma on metastasis and survival. Cancer 65:1119-1129, 1990
7. Gustafson P, Rööser B, Rydholm A: Is local recurrence of minor importance for metastases in soft tissue sarcoma? Cancer 67:2083-2086, 1991
8. Creech OJ, Krementz ET, Ryan RF, et al: Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit. Ann Surg 148:616-632, 1958
9. Benckhuijsen C, Kroon BBR, Van Geel AN, et al: Regional perfusion treatment with melphalan for melanoma in a limb: Evaluation of drug kinetics. Eur J Surg Oncol 14:157-163, 1988
10. Thompson JF, Gianoutsos MP: Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 61:227-233, 1992
11. Krementz ET, Carter RD, Sutherland CM, et al: Chemotherapy of sarcomas of the limbs by regional perfusion. Ann Surg 185:555-564, 1977
12. McBride CM: Sarcomas of the limbs: Result of adjuvant chemotherapy using isolation perfusion. Arch Surg 109:304-308, 1974
13. Stehlin JS, de Ipolyi PD, Giovanella BC, et al: Soft tissue sarcomas of the extremity: Multidisciplinary therapy employing hyperthermic perfusion. Am J Surg 130:643-646, 1975
14. Lethi PM, Stephens MH, Janoff K, et al: Improved survival for soft tissue sarcoma of the extremities by regional hyperthermic perfusion, local excision and radiation therapy. Surg Gynecol Obstet 162:149-152, 1986
15. Hoekstra HJ, Schraffordt Koops H, et al: Results of isolated regional perfusion in the treatment of malignant soft tissue tumors of the extremities. Cancer 60:1703-1707, 1987
16. Braat RP, Wieberdink J, van Slooten EA, et al: Regional perfusion with Adriamycin in soft tissue sarcomas. Recent Results Cancer Res 86:260-263, 1983
17. Klaase JM, Kroon BBR, Benckhuysen C, et al: Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer 64:616-621, 1989
18. Rossi CR, Vecchiato A, Foletto M, et al: Phase II study on neoadjuvant hyperthermic-antiplastic perfusion with doxorubicin in patients with intermediate of high grade limb sarcomas. Cancer 73:2140-2146, 1994
19. Filippo FD, Calabro AM, Cavallari A, et al: The role of hyperthermic perfusion as a first step in the treatment of soft tissue sarcomas of the extremities. World J Surg 12:332-339, 1988
20. Liénard D, Delmotte JJ, Renard N, et al: High doses of rTNF-αa in combination with IFN-gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10:52-60, 1992
21. Trojani M, Contesso G, Coindre JM, et al: Soft-tissue sarcomas of adults; Study of pathologic prognostic variables and definition of a histopathological grading system. Int J Cancer 33:37-42, 1984
22. Hoekstra HJ, Naujocks T, Schraffordt Koops H, et al: Continuous leakage monitoring during hyperthermic isolated regional perfusion of the lower limb: Techniques and results. Reg Cancer Treat 4:301-304, 1992
23. Klaase JM, Kroon BBR, Van Geel AN, et al: Systemic leakage during isolated limb perfusion for melanoma. Br J Surg 80:1124-1126, 1993
24. World Health Organization: Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication no. 48. Geneva, Switzerland, World Health Organization, 1979
25. Wieberdink J, Benckhuijsen C, Braat RP, et al: Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 18:905-910, 1982
26. Wanebo HJ, Temple WJ, Popp MB, et al: Preoperative regional therapy for extremity sarcoma: A tricenter update. Cancer 75:2299-2306, 1995
27. Suit HD, Proppe KH, Mankin HJ, et al: Preoperative radiation therapy for sarcoma of soft tissue. Cancer 47:2269-2274, 1981
28. Rouësse JG, Friedman S, Sevin DM, et al: Preoperative induction chemotherapy in the treatment of locally advanced soft tissue sarcomas. Cancer 60:296-300, 1987
29. Shiu M, Hilaris B, Harrison LB, et al: Brachytherapy and function saving resection of soft-tissue sarcoma arising in the limb. Int J Radiat Oncol Biol Phys 21:1485-1492, 1991
30. 31P magnetic resonance spectroscopy as predictor for clinical response in human extremity sarcomas treated by single dose TNFα + melphalan isolated limb perfusion. NMR Biomed 8:215-224, 1995
31. Nieweg OE, Pruim J, Hoekstra HJ, et al: Positron emission tomography with fluorine-18-fluorodeoxyglucose for the evaluation of therapeutic isolated regional limb perfusion in a patient with softtissue sarcoma. J Nucl Med 35:90-92, 1994
32. Hill S, Fawcett WJ, Sheldon J, et al: Low-dose tumour necrosis factor α and melphalan in hyperthermic isolated limb perfusion. Br J Surg 80:995-997, 1993
33. Vaglini M, Belli F, Ammatuna M, et al: Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon and melphalan. Cancer 73:483-492, 1994
34. Thorn AK, Alexander HR, Andrich MP, et al: Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan. J Clin Oncol 13:264-273, 1995
35. Swaak AJG, Liénard D, Schraffordt Koops H, et al: Effects of recombinant tumour necrosis factor (rTNF-α) in cancer. Observations on the acute phase protein reaction and immunoglobulin synthesis after high dose recombinant TNF-α administration in isolated limb perfusions in cancer patients. Eur J Clin Invest 23:812-818, 1993
36. Lejeune FJ, Liénard D, Eggermont AMM, et al: Clinical experience with high-dose tumor necrosis factor alpha in regional therapy of advanced melanoma. Circ Shock 43:191-197, 1994
37. Posner M, Liénard D, Lejeune FJ, et al: Hyperthermic isolated limb perfusion (HILP) with tumor necrosis factor (TNF) alone for metastatic intransit melanoma. Proc Am Soc Clin Oncol 13:1351, 1994 (abstr)
38. Manusama ER, Nooijen PTGA, Stavast J, et al: Synergistic antitumour effect of recombinant tumour necrosis factor α with melphalan in isolated limb perfusion in the rat. Br J Surg 83:551-555, 1996
39. Spriggs DR, Sherman ML, Michie H, et al: Recombinant human tumor necrosis factor administered as a 24 h intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst 80:1039-1044, 1988
40. Blick MB, Sherwin SA, Rosenblum M, et al: A phase I trial of recombinant human tumor necrosis factor in cancer patients. Cancer Res 47:2986-2989, 1987
41. Chapman PB, Lester TJ, Casper ES, et al: Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol 5:1942-1951, 1987
42. Feinberg B, Kurzrock R, Talpaz M, et al: A phase I trial of intravenously administered recombinant tumor necrosis factor alpha in cancer patients. J Clin Oncol 6:1328-1334, 1988
43. Asher AL, Mule JJ, Reichert CM, et al: Studies of the antitu mor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 138:963-974, 1987
44. Carswell EA, Old LJ, Kassel RL, et al: An endotoxin induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72:3666-3370, 1975
45. Sugarman BJ, Aggarwal BB, Mass PE, et al: Recombinant tumor necrosis factor-alpha: Effects on proliferation of normal and transformed cells in vitro. Science 230:943-945, 1985
46. Renard N, Liénard D, Lespagnard L, et al: Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (TNFα). Int J Cancer 57:656-663, 1994
47. Renard N, Nooijen PTGA, Schalkwijk L, et al: VWF release and platelet aggregation in human melanoma after perfusion with TNFα. J Pathol 176:279-287, 1995
48. Watanabe N, Niitsu Y, Umeno H, et al: Toxic effect of TNF on tumor vasculature in mice. Cancer Res 49:2179-2183, 1988
49. Sato N, Goto T, Haranaka K, et al: Actions of TNF on cultured vascular endothelial cells: Morphological modulation, growth inhibition and cytotoxicity. J Natl Cancer Inst 76:1113-1121, 1986
50. Bloksma N, van de Wiel PA, Kuper CF, et al: Multiple facets of induction of tumor necrosis. Ann Inst Pasteur/Immunol 139:294-299, 1988
51. Nawroth P, Handley D, Matsueda G, et al: TNF/cachectin-induced intravascular fibrin formation in Meth-A fibrosarcomas. J Exp Med 168:637-647, 1988
52. Manusama ER, Stavast J, Marquet RL, et al: Total body irradiation (TBI) attenuates antitumor effects of TNFα in isolated limb perfusions (ILP) in the rat. Eur J Surg Res 27:110, 1995 (suppl 1, abstr)
53. Prograbniak HW, Witt CJ, Terrill R, et al: Isolated lung perfusion with tumor necrosis factor : A swine model in preparation of human trials. Ann Thorac Surg 57:1477-1483, 1994
54. Fraker DL, Alexander HR, Thorn AK: Use of tumor necrosis factor in isolated hepatic perfusion. Circ Shock 44:45-50, 1994
55. Vries de MR, Borel Rinkes IHM, Wiggers T, et al: Hyperthermic isolated hepatic perfusion with TNF̈ with and without melphalan in 3 pigs. Eur J Surg Res 27:81, 1995 (suppl 1, abstr)
56. Veen van de AH, Manusama ER, Kampen van CA, et al: Tumor necrosis factor-α (TNFα) in isolated kidney perfusions in rats: Toxicity and antitumor effects. Eur J Surg Oncol 20:404-405, 1994